Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 4/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | ROS1 | P08922 | 1/20 | 0.33 |
| ▸ | MARK3 | P27448 | 1/20 | 0.33 |
| ▸ | LTK | P29376 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.33 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.33 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2145268 | 0.83 | TRPA1 (0.36) | TRPA1PNMTASIC3CHEK2ROS1 | |
| Hydrochloric Acid SCHEMBL14921733 | 0.81 | TRPA1 (0.35) | TRPA1PNMTASIC3METAP1ADRA2A | |
| SCHEMBL6161601 | 0.79 | TRPA1 (0.45) | TRPA1PNMTASIC3CHEK2ROS1 | |
| Hydrochloric Acid SCHEMBL6962514 | 0.78 | TRPA1 (0.44) | TRPA1PNMTASIC3CHEK2ROS1 | |
| SCHEMBL18023177 | 0.74 | MAPT (0.35) | KDRADRA2A | |
| SCHEMBL19374125 | 0.70 | NPSR1 (0.36) | TRPA1 | |
| SCHEMBL5072285 | 0.69 | TRPA1 (0.44) | TRPA1PNMTASIC3CHEK2ROS1 | |
| SCHEMBL15528512 | 0.69 | TRPA1 (0.51) | TRPA1PNMTKDM1A | |
| SCHEMBL7341198 | 0.67 | KDM1A (0.40) | TRPA1PARP1PARP10KDM1ABRD4 | |
| SCHEMBL7680089 | 0.67 | TRPA1 (0.35) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-20230382912-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-30 | — | — | US | disclosed |
| US-11814381-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-14 | — | — | US | disclosed |
| US-20230144841-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9878992-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170342048-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2017-11-30 | — | — | US | disclosed |
| US-9688654-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9630958-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2017-04-25 | — | — | US | disclosed |
| US-9543538-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-01-10 | — | — | US | disclosed |
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2015-07-16 | — | — | US | disclosed |
| US-20150190457-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2015-07-09 | — | — | US | disclosed |
| US-8999966-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140107073-A1 | GDF-8 Inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140045859-A1 | Glucokinase Activators | TAKEDA CALIFORNIA, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130237518-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP | 2013-09-12 | — | — | US | disclosed |
| US-20120225887-A1 | Glucokinase Activators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-06 | — | — | US | disclosed |
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2006065809-A2 | HETEROATOM BRIDGED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144841-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FAP, FIBP, FRS2 | TRPA1 3359/4885PNMT 4710/4885ASIC3 4007/4885 |
| US-20140107073-A1 | GDF-8 Inhibitors | MSTN, MYOF, CXCL8 | TRPA1 4474/4885PNMT 4880/4885ASIC3 3418/4885 |
| US-20230382912-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | TRPA1 93/4885PNMT 2988/4885ASIC3 369/4885 |
| US-20150190457-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | C5, C9, TFPI | TRPA1 839/4885PNMT 1183/4885ASIC3 3759/4885 |
| US-20130237518-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAP3K20 | TRPA1 4158/4885PNMT 4020/4885ASIC3 4456/4885 |
| US-20170342048-A1 | GDF-8 Inhibitors | MSTN, MYOF, CXCL8 | TRPA1 4474/4885PNMT 4880/4885ASIC3 3418/4885 |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | TRPA1 438/4885PNMT 2021/4885ASIC3 2874/4885 |
| US-20140045859-A1 | Glucokinase Activators | GCK, GCKR, GALK1 | TRPA1 4472/4885PNMT 4200/4885ASIC3 3184/4885 |
| US-11814381-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | TRPA1 173/4885PNMT 2528/4885ASIC3 298/4885 |
| US-20120225887-A1 | Glucokinase Activators | GCK, GCKR, GALK1 | TRPA1 4472/4885PNMT 4200/4885ASIC3 3184/4885 |
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | MTOR, PIK3R5, PIK3R2 | TRPA1 1359/4885PNMT 4118/4885ASIC3 4272/4885 |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | PTPN1, PTPN9, PTPN7 | TRPA1 3421/4885PNMT 4641/4885ASIC3 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.